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Abstract Growth failure is a common and significant
clinical problem for children on dialysis and often remains
a major impediment to their rehabilitation. Early referral to
a paediatric nephrology centre and appropriate management
before the initiation of dialysis may significantly prevent
growth deterioration. Growth in children on dialysis can be
affected by nutritional, metabolic, and hormonal changes.
Early diagnosis of malnutrition and aggressive management
should be a priority. Gastrostomy feeding should be used
when adequate oral intake to maintain normal height and
weight velocity cannot be achieved. Active vitamin D
metabolites should be used carefully, to prevent low-
turnover bone disease. All children should have an
adequate regimen of dialysis and an appropriate manage-
ment of malnutrition, renal osteodystrophy, metabolic
acidosis, salt wasting and anaemia, before recombinant
human growth hormone (rhGH) administration is consid-
ered. The current challenge of reversing growth impairment
in children on dialysis can only be achieved by optimiza-
tion of their care.
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Introduction
It has long been recognized that growth retardation is a
common complication of children on dialysis [1, 2]. This
problem remains a concern today, despite the radical
improvements in their management over the past two
decades. This concern has recently increased, because poor
growth of children with chronic kidney disease (CKD) has
been associated with increased risk of hospitalization and
death [3]. The most common causes of hospitalization in
these patients are infections, possibly related to their poor
nutritional status. Therefore, although poor growth is
unlikely to be the cause of this increased morbidity, growth
failure may be a marker of untoward events [3]. The
decrease of height velocity before and during the dialysis
period frequently results in diminished final adult height
[4]. Children with extremely short stature face a disability
that may affect their psychological and social well-being
[5]. In this issue of Pediatric Nephrology Cansick and co-
workers report on the growth of 35 prepubertal children
who have been on dialysis for more than 1 year [6]. The
results of this retrospective study are encouraging, since the
majority of patients had no deterioration of their growth. In
addition, catch-up growth was observed in some children
under 2 years of age within the first dialysis year. This was
achieved with intensive medical and nutritional therapy.
Ninety-one percent of patients received supplementary
enteral feeding, either by nasogastric tube or by gastro-
stomy tube for some or all of the study period. In addition,
all patients had meticulous management of their renal
osteodystrophy, and the median parathyroid hormone
(PTH) level was 1.5-times the upper limit of normal [6].
These excellent results were accomplished without the daily
administration of recombinant human growth hormone
(rhGH).
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Growth retardation in children on dialysis is the consequence
of a combination of several inter-related processes, which are
partially understood. The major factors responsible include
malnutrition, metabolic bone disease, anaemia, salt-wasting
disorders, metabolic acidosis, reduced responsiveness to endog-
enous growth hormone (GH) and insulin-like growth factor
(IGF)-I and other endocrine abnormalities [7]. The positive
effect of adequate dialysis on growth is also well documented
in patients on peritoneal dialysis (PD) [8, 9]. A subset of
children on dialysis may still have poor linear growth, despite
the optimal management of all the treatable factors. For these
patients the administration of rhGH is recommended.
Management of growth retardation before the initiation
of dialysis
Data on growth of 2,329 children in the North American
Pediatric Renal Transplant Cooperative Study (NAPRTCS)
revealed that the mean height standard deviation score (SDS) at
the initiation of dialysis was −2.54, −1.95, and −1.67 for chil-
dren aged 0 to 1 years, 2 to 5 years and 6 to 12 years, re-
spectively [10]. The results of the study by Cansick et al. were
similar: the mean SDS at the start of dialysis was −2.1 [6].
This means that 50% of the prepubertal children of this study
had poor growth at the initiation of dialysis, despite the
adequate nutritional care that is provided in this centre. Those
findings suggest that the strategies for growth improvement
before dialysis were suboptimal and should definitely be im-
proved. In addition, this shows that rhGH before the initiation
of dialysis is not widely used. Late referral to a paediatric
nephrology centre might partially explain these findings.
Several recent studies on adults have documented that late
referral may significantly contribute to significant complica-
tions with dialysis [11–13]. A recent multicentre study from
Poland found that 21% of 180 children started dialysis within
1 month after their first referral to a nephrologist and were
classified as late referrals. These children had a body mass
index below the 10th percentile significantly more often than
children with early referral [14]. Early referral followed by
appropriate nutritional management may lead to prevention of
growth deterioration. However, if conservative management is
not effective, rhGH should be administered before the
initiation of dialysis. Short children on conservative manage-
ment respond better to rhGH than do children on dialysis [15].
Early referral may also result in early initiation of dialysis and
preservation of residual renal function (RRF). There is
evidence that RRF has a positive effect on growth of children
on PD [8].
The effect of dialysis modality on growth
The initiation of haemodialysis (HD) usually does not
improve growth [1]. Actually, a mean of 0.4–0.8 height SD
was lost per year in various studies [1, 16]. Recent data
from the Annual Report of NAPRTCS are more optimistic.
[10]. It is of interest that an annual height gain of 0.3 SD
was observed in 12 children on long-term HD treated with a
combination of adequate nutrition and with dialysis urea
clearances exceeding conventional recommendations (mean
Kt/Vurea of 2, and average time of HD of 15 h/week) [17].
Studies on adults show superior dialysis adequacy on slow
nocturnal HD compared with conventional HD. It is
expected that this technique will have a positive effect on
growth. Presently, there are no data on growth of children
on slow nocturnal HD. However, a recent preliminary
report suggests the potential efficacy of in-centre intensified
and daily HD, delivered five to six times weekly, for 3 h
each session. Five children treated with this regimen had a
mean change of +1.84 height SDS/year [18].
Despite some optimistic early reports on growth of
children on PD [2, 19], more recent studies confirm
percentile-parallel growth patterns in the majority of patients.
Changes from baseline of mean height SDS were −0.04 (n=
1,320) and −0.09 (n=525) at 12 months and 24 months of
PD, respectively, at the 2006 Annual Report of NAPRTCS.
For children on HD, these changes were −0.14 (n=573) and
−0.43 (n=276) at 12 months and 24 months [10]. The
majority of children at initiation of PD are younger than
patients on HD, and this selection might explain the above
differences in growth. There is evidence that growth of
children on dialysis is better during the first 2 years of life.
This has been confirmed by the study by Cansick et al. [6].
In addition, changes from baseline of mean height SDS of
patients less than 1 year were 0.27 (n=263) and 0.40 (n=
100) at 12 months and 24 months of dialysis in the report of
NAPRTCS [10]. The growth data of 51 children and
adolescents on PD from 16 mid-European paediatric dialysis
centres were similar to those of NAPRTCS. The mean height
(SDS) was −2.0 at the start of PD. During the 18-month
study period, the degree of growth retardation did not change
significantly (mean height SDS −2.1) [20]. The risk of losing
height SDS was increased in high transporters, who
exhibited an average loss of 0.5 SD units per year of
dialysis [20]. Dialytic creatinine clearance and total dialysate
volume were significant predictors of the change in height
SDS in these patients [20]. Therefore, optimal prescription of
volume should be a priority for all children on PD, and this
can be achieved with the adherence to guidelines for the
paediatric peritoneal dialysis prescription [21]. In children, a
Kt/Vurea over 2 has to be achieved, but this may be difficult
in those who are anephric or have minimal residual function
[21]. Better growth results in children on PD are described in
single-centre studies. Catch-up growth occurred in 62% of
21 children on PD in a study from Helsinki [22]. The
primary renal disease of the children under 5 years of age
was mainly congenital nephrotic syndrome, with mutation in
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the nephrin gene (NPHS1). The 9-month change in height
SDS in patients under 5 years of age was significantly better
in patients under 5 years of age than in the older patients
[22]. Despite the fact that only one patient received rhGH,
the mean height SDS of the group increased from −1.3±1.2
at baseline to −0.8±1.0 at 9 months. This was probably the
result of augmented weekly mean solute clearances (Kt/
Vurea: 3.2±0.6 and creatinine clearance 69±17 l/1.73 m
2
body surface area per week) [22]. Similarly, McCauley et al.
reported catch-up growth in nine of 15 children treated with
PD [23].
There is evidence for a positive influence of residual
renal function on the growth of children receiving PD [8,
24]. Catch-up growth was observed in 58% of children with
RRF, but such growth was seen only in 17% of 12 patients
without RRF [8]. It is of interest that patients with and
without RRF had near-equal total Kt/Vurea values. These
findings challenged the concept of the equivalence of solute
removal by native kidney function and by dialysis and
documented the superiority of RRF. Better preservation of
RRF with PD than with HD was reported in adult [25] and
paediatric [26] patients. It has been recently reported that
RRF appears to play a greater role in paediatric patients on
HD than was previously recognized, by improving dietary
prescription and hypertension [27]. The maintenance of
RRF also has implications for morbidity in adult dialysis
patients by causing better dialysis clearance, elimination of
middle molecules and β2-microglobulin, and improved
fluid–electrolyte balance and cardiovascular morbidity [28].
Recently, an improvement in the growth of children on
dialysis was reported. In 1987, patients receiving their initial
transplant were an average of 2.4 standard deviations below
average [10]. This improved to −1.6 in the 2005 cohort of
NAPRTCS. However, in the same cohort, the average
height SDS was −2.6 for children 2–5 years of age [10]. In
addition, the weakness of the NAPRTCS report is the fact
that all the analyses regarding growth are based on cross-
sectional data and not on longitudinal data. For this reason,
the number of patients is changing at the time intervals of
the report. The comparison of the cross-sectional data from
1987 to cross-sectional data differently collected in 2006 is
a weakness of the study, and this is the major criticism of
the optimistic information of this report.
Assessment of malnutrition
Caloric deficiency and abnormal protein metabolism may
play an important role in growth impairment, particularly in
younger children. This problem is common in children on
dialysis [29, 30] and is usually mild [31, 32]. Malnutrition
in our day is less often noted than in the past; however, it is
still seen in many centres. There is a lack of generally
accepted criteria for the diagnosis of this problem. In
addition, there is a problem with the interpretation of
weight (and body mass index) in dialysis patients because
of the difficulties in estimating their true dry weight. Bio-
electrical impedance (BIA) is a promising technique for the
assessment of the state of hydration [31, 33]. The lack of
invasiveness, and the low cost of this method, make it very
attractive. In addition, with this technique, it is easy to
calculate whole-body percentage fat-free mass (FFM) [34].
These calculations are based on the assumption that the
percentage of water of the FFM is stable (73%). However,
in children on dialysis, this assumption is not always true,
and, therefore, FFM prediction might be extremely prob-
lematic. Mid-upper arm circumference and skinfold thick-
ness measurements from many sites are widely used for
estimating body composition [35]. Despite the limited
precision of these measurements, acceptable reproducibility
can be achieved with skinfold thickness measurements, and
these are useful for monitoring changes over time.
Recently, a nutritional score was developed, based on the
following three groups of parameters: anthropometry 1
(height, weight, body mass index), anthropometry 2 (mid-
arm muscle circumference, arm muscle area, and arm fat
area) and BIA (reactance, phase angle, and distance) [31].
Each parameter received a score of 5 for values of >0 SDS;
4 for values of 0 and >−1 SDS; 3 for values of −1 and >−2
SDS; 2 for values of −2 and >−3 SDS; and 1 for values of −3
SDS. An average score was calculated for each of the three
groups, and these were added to obtain the anthropometry-
BIA nutrition (ABN) score, which could vary from 3
(worst) to 15 (best). The ABN score corresponding to the
3rd percentile in the population of healthy children was
10.3. Therefore, the patients with ABN scores of <10.3
were classified as malnourished. It is of interest that, when
using this score, a recent Italian multicentre study found
that 48% of children on PD were malnourished [31].
However, the percentage of children with scores suggesting
severe malnutrition (ABN score of <6) was very low
(2.3%), whereas moderate (ABN scores of 6–8) and mild
(ABN score of 8–10.3) malnutrition were equally distrib-
uted. This ABN score is a simple method for the assess-
ment of the nutritional status and might prove to be very
useful for identifying children with mild and moderate
malnutrition [31].
Serum albumin concentration was frequently used as a
reliable biochemical marker for nutritional status. However,
the presence of acute or chronic inflammation limits the
specificity of serum albumin as a nutritional marker [35].
Low values of serum albumin are closely related to the
presence of inflammation. Serum albumin has been
identified as a surrogate marker for morbidity/mortality in
adult dialysis patients. It is of interest that paediatric
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patients who are started on dialysis when they exhibit hypo-
albuminaemia are also at a higher risk of death [36].
Therefore, it is of concern that the prevalence rate of hypo-
albuminaemia (serum albumin of <2.9 g/dl) in children on
PD was higher than that of adults (35.9% versus 19.5%; P<
0.004) [37]. Hypo-albuminaemia in children on PD was
associated with a low protein catabolic rate, which was
indicative of insufficient protein intake for their obligate
protein losses during PD. This inadequate protein intake was
considered responsible for the poor growth of patients [37].
Management of malnutrition
Children on dialysis are often anorectic. Poor energy intake
is the result of many factors, including psychological dis-
turbances. Provision of sufficient energy is considered the
most important factor in preventing poor growth in children
on dialysis. The negative effect of malnutrition on growth
during the first 2 years of life is well documented [38, 39].
Adequate provision of energy intake in infancy and early
childhood can lead to catch-up growth [40]. However, a
similar effect was not usually observed in older children
[41], possibly because the nutritional management of these
patients was not optimal. The initial prescribed energy
intake for children treated with maintenance HD or
peritoneal dialysis should be at the recommended dietary
allowance (RDA) level for chronological age, since there is
no evidence that children on dialysis require a higher RDA
than do healthy children. Modifications should then be
made depending upon the child’s response [35]. Children
on dialysis should have their initial dietary protein intake
based on the RDA for chronological age, with an additional
increment of 0.4 g/kg per day for patients on HD, or their
anticipated peritoneal losses for children on PD [35]. In
many young children these goals can be accomplished only
by supplementary enteral feeding. Of 101 children with
severe chronic renal failure, presenting within the first
6 months of life at the Great Ormond Street Hospital for
Sick Children in London, 81% were enterally fed for a
median of 1.9 years. Catch-up growth occurred in many
patients in the study [40]. Nasogastric tube feeding has
been the most frequently used approach for nutritional
support in children on PD [42]. However, with this
technique, gastro-oesophageal reflux and aspiration remains
a concern [43]. Eating difficulties following the withdrawal
of nasogastric tube feeding is also an important problem,
especially when it is initiated during the first year of life
[44]. To avoid these problems, many centres prefer the use
of gastrostomy feeding [45, 46]. In children on PD a gas-
trostomy should be created as on open procedure, where the
stomach is directly connected to the anterior abdominal
wall, with an initial Foley balloon catheter and subsequent
insertion of a gastrostomy button [43]. The alternative
approach to creating a gastrostomy is to use percutaneous
endoscopic gastrostomy (PEG) [47]. However, this tech-
nique is frequently associated with the development of
peritonitis in PD patients and should be used before the
initiation of PD. It was recently reported that ten of 27 of
children (37%) on PD developed peritonitis within 7 days
of PEG insertion, and fungal peritonitis occurred in seven
of 27 (26%) [47].
It is of interest that the requirements for energy intake
was 125% of that recommended to achieve catch-up growth
[48]. Although sufficient energy intake is usually recom-
mended for children with growth retardation, an exagger-
ated calorie intake should be avoided [49]. An excessive
energy intake may induce hyperlipidaemia and hyperinsu-
linism [49]. It is also associated with high leptin levels,
which may contribute to lack of appetite [50]. Therefore,
body mass index should be regularly calculated and must
remain within the normal limits. An excessive protein intake
should also be avoided in children on dialysis, to prevent
metabolic acidosis, hyperphosphataemia and the accumula-
tion of toxic nitrogen waste products.
Renal bone disease and growth
Childhood renal osteodystrophy (ROD) is the consequence
of disturbances of the calcium-regulating hormones
vitamin D and PTH [51], as well as of the somatotroph
hormone axis associated with local modulation of bone and
growth cartilage function [52]. Although gross symptoms
of renal osteodystrophy (bone deformities) are usually not
noted in children with glomerular filtration rate (GFR) >
50 ml/min per 1.73 m2 body surface area, histological ab-
normalities of bone formation can already be noted in up to
50% of untreated patients [53]. Renal osteodystrophy
affects growth not only as a consequence of gross bone
deformities, but also by more subtle changes in growth
plate cartilage function and in bone formation. Experimen-
tal data demonstrate several alteration of the growth plate
and/or growth plate chondrocyte function. Both the severity
and duration of renal failure may affect the growth plate
differently [54]. Both the activity of the growth plate
cartilage, by altering chondrocyte hypertrophy, and the
replacement of cartilage by bone at the metaphyseal end are
affected. The two processes are differentially depressed,
since cartilage resorption is more severely lowered than is
cartilage enlargement, and this leads to an accumulation of
cartilage at the hypertrophic zone [55]. Therefore, growth
plate proliferation as well as differentiation are affected by
the uraemic state. A decreased immunohistochemical
detection of growth hormone receptor [56] and insulin-like
growth factor-I mRNA [57] in the proliferative zone of the
uraemic growth plate was reported. The following sections
concentrate on the effects of vitamin D and PTH on growth.
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The role of vitamin D
Already by the 1980s, Chesney et al. had documented the
effect of calcitriol in preventing severe bone deformities in
children with chronic renal failure (CRF) and had shown
catch-up growth [51]. In experimental models catch-up
growth was also observed in uraemic animals treated with
vitamin D or active vitamin D metabolites. However, the
improved growth could not solely be contributed to the
effects of vitamin D alone [58]. In addition, this positive
effect on growth could not be sustained for long periods.
Supplementation with vitamin D3 and active vitamin D
metabolites is essential, not only to regulate PTH produc-
tion, but also for normal growth plate cartilage growth and
differentiation in vitro [59, 60] and in vivo [61, 62].
However, high doses of calcitriol were shown to inhibit
cartilage proliferation in vitro [59, 60] and in vivo [61, 62].
Calcitriol exerts a biphasic effect on chondrocyte prolifer-
ation in vitro. Low concentrations were shown to stimulate
growth plate chondrocyte proliferation, whereas high
concentrations showed an inhibitory effect in vitro [59,
60]. In animal experiments, intermittent high doses of
calcitriol inhibited longitudinal growth and even abrogated
the effect of growth hormone [62, 63]. Reduced growth
from intermittent high doses of calcitriol was also reported
in children on PD [64], but not in a controlled study in
prepubertal children with pre-terminal renal failure in
whom PTH was maintained at 2–3 times the upper limit
of normal [65]. In children as well as in adult patients high-
dose intermittent calcitriol regimens might result in sup-
pressed bone formation (adynamic bone disease).
Role of parathyroid hormone
Parathyroid hormone acts on the growth plate and on bone.
In uraemia the amount of PTH/PTH-related protein receptor
mRNA in bone cells [66] and in the animal growth plate
[61, 67, 68] was found to be reduced, indicating a peripheral
resistance to the action of PTH. Therefore, higher PTH
concentrations were advocated for patients with CRF.
Adynamic bone lesions were reported with PTH levels up
to three-times the upper limit of normal [69]. When PTH
serum levels are suppressed to normal values by active
vitamin D metabolites, the risk of hypercalcaemia is
increased, due to the inability of bone to incorporate
calcium [70]. The guidelines of the Kidney Disease Out-
comes Quality Initiative (KDOQI), as well as the recom-
mendations by the European Pediatric Dialysis Working
Group (EPDWG), recommend PTH levels within normal
range in CKD stages 2–3 and up to three-times normal in
stage 5 [71, 72]. It is not known which PTH levels should
be aimed at in children with stage 4 CKD. Higher levels of
PTH are often associated with hyperparathyroid bone
disease. Marked hyperparathyroidism was associated with
a trend to reduced growth in the retrospective study by
Waller et al. [73]. Stunting of growth in marked hyperpara-
thyroidism could be due to altered growth cartilage
function, as demonstrated in animal [61] and in vitro [60]
experiments. Osteopenia was also increased in children
with CRF with high PTH levels (>200 pmol/l) [74]. Bone
mineral density was positively correlated with calcium and
negatively with PTH and phosphorus serum levels [74]. In
healthy adolescent girls PTH correlated inversely with bone
mineral content [75]. In concordance with these guidelines,
Waller et al. documented catch-up growth using a strict
regime of phosphorus and calcium control in combination
with enteral tube feeding and maintenance of PTH within
the normal upper range in children with CKD stages 2–4
[73]. The same group report in this issue of the Journal [6]
that there was no deterioration of growth of children on
dialysis when PTH levels remained within 1.5-times the
upper limit of normal. Children on dialysis who were below
the (height)–age of 2 years even showed catch-up growth.
This is in line with the physiological concept that
longitudinal growth is mainly dependent on adequate
caloric and protein intake within the first 2 years. In older
children the action of growth hormone overrides the
nutritional effect.
Biochemical markers
The validity of biochemical assessment of bone turnover in
advanced renal failure is still being debated. There are
several markers of bone formation and bone resorption in
adults [76, 77] as well as in children with CKD [78, 79].
The disadvantage of most markers is their low sensitivity
and specificity to discriminate between the main types of
renal bone disease, i.e. low-turnover (adynamic), normal
and high-turnover bone formation. In adult dialysis
patients, total alkaline phosphatase, as well as bone alkaline
phosphates, predicted normal bone formation rate and
adynamic bone disease taken as a group together versus
high-turnover bone disease, with a sensitivity of 76% and
specificity of 60% [77]. Bayazit and co-workers [79], as
well as the group of Avila-Diaz [80], reported a correlation
of PTH and alkaline phosphatase in children on dialysis. In
the latter group, patients with PTH of less than 150 pg/ml
were classified as low bone turnover patients. In these
patients, alkaline phosphatase did not correlate with growth
parameters. However, a positive correlation of alkaline
phosphatase, but not of PTH serum levels, with growth was
reported in the paper by Cansick et al. [6]. In another study
a significant correlation was found between bone-specific
alkaline phosphatase, as well as total alkaline phosphatase,
and growth velocity in the preceding 6 months in children
with CKD [81]. Possibly, this was the result of the absence
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of significant adynamic or high turnover bone disease,
since there is a correlation between alkaline phosphatase
and bone formation rate. This was achieved with the careful
use of active vitamin D metabolites, which were shown to
increase the incidence of low-turnover bone disease. It is
well documented that low-turnover bone disease, as well as
high-turnover bone disease (osteitis fibrosa), are associated
with reduced growth. Cansick et al. report, in this issue of
the Journal, a trend of reduced growth (though not sig-
nificant) in the group of children with grossly elevated PTH
serum levels compared with those with PTH up to three-
times the upper limit of normal. However, owing to the
retrospective design of the study, there was no histological
evaluation of the bone.
Treatment of renal growth failure with recombinant growth
hormone
During the first 2 years of life, nutrition is the most
important factor for growth. However, during childhood,
the role of the somatotropic hormone axis becomes more
important. The growth pattern during this period is usually
parallel to the percentile curves, and it has been interpreted
as “normal” growth, but this is underestimating the growth
problem [7]. The standard deviation of height increases
with age, and a male child with a height SDS of −3 in his
1st year of life has a height 7.6 cm below the median for his
age and gender. This deficit will increase to 12.5 cm and
16.5 cm for this patient if his height SDS remains the same
(−3) at the age of 4 years and 8 years, respectively [7].
Therefore, early management of growth retardation is
crucial to avoid permanent reduction of height, and rhGH
administration should be considered in the cases where
nutritional intervention is not successful. The current
guidelines recommend that rhGH be administered to
children with CKD who have a height or height velocity
for chronological age of below −2 SDS [34]. These
guidelines also recommend that rhGH be prescribed once
it is assured that provision of energy, protein, and micro-
nutrients is adequate and that metabolic acidosis, hyper-
phosphataemia, and secondary hyperparathyroidism have
been managed. This is fundamental for children with
diminished height velocity and normal height SDS. An
increase in resting energy expenditure has been described in
children treated with rhGH, possibly related to increased
protein turnover. Therefore, meticulous nutritional care should
also be provided during the period of rhGH treatment. [82].
The positive effect of rhGH treatment on growth of
dialysis patients is well documented. Fourteen patients on
HD and 17 patients on PD were treated with rhGH for at
least 12 months. The HD and PD patient groups were
comparable with regard to age, bone age, height SDS, and
height velocity at the start of treatment. During the first year
of rhGH treatment, a nearly twofold increase in height
velocity occurred in both groups. However, the efficacy of
treatment decreased considerably during the second treat-
ment year [83]. In addition, it is well documented that
prepubertal growth acceleration with rhGH administration
is not associated with a disproportionate advancement of
bone age. These results were confirmed in a multicentre
French study of 42 children on HD, with a height SDS
below −2.0. During the first year of rhGH treatment there
was a 0.5 mean SDS height gain [84]. Kari and Rees had
similar results, in which the mean height SDS at the same
period was increased by 0.4 [85]. Prepubertal children with
CKD on conservative treatment respond better to rhGH
than children on dialysis. In a German multicentre study it
was found that the height gain of 41 patients on conservative
treatment was 1.3 SDS, on average, during the first two
treatment years compared with 0.8 SDS in 13 dialysis
patients [15]. Despite evidence of rhGH efficacy and safety,
the frequency of rhGH administration in children on dialysis
remains low. This is partially explained by the lack of clear
guidelines regarding the initiation and monitoring of GH
therapy in children with CKD. Therefore, an algorithm has
been developed recently for the rational evaluation and
treatment of growth failure in this population by members of
the consensus committee, outlining their recommendations for
appropriate steps to improve growth [86].
The growth of children on dialysis has significantly
improved during the past decade [10]. This is possibly the
result of earlier referral, modern dialysis, appropriate
nutritional management, the careful use of metabolites of
vitamin D3, the use of recombinant human erythropoietin
and, finally, the administration of recombinant human
growth hormone. However, the growth of children 2–5 years
of age remains a concern, and more aggressive nutritional
management and wider use of recombinant human growth
hormone might be required.
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